{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:01:16Z","timestamp":1792450876701,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Faculty of Medicine Ramathibodi Hospital, Mahidol University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54471-7","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:25:27Z","timestamp":1779805527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Epstein\u2013Barr virus-specific T-cells in pediatric liver transplant recipients"],"prefix":"10.1038","volume":"16","author":[{"given":"Songpon","family":"Getsuwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nopporn","family":"Apiwattanakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatmanee","family":"Lertudomphonwanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suradej","family":"Hongeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophida","family":"Boonsathorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiparat","family":"Manuyakorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornthep","family":"Tanpowpong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usanarat","family":"Anurathapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suporn","family":"Treepongkaruna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"54471_CR1","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1002\/jmv.26202","volume":"92","author":"Y Yang","year":"2020","unstructured":"Yang, Y. & Gao, F. Clinical characteristics of primary and reactivated Epstein\u2013Barr virus infection in children. J. Med. Virol. 92, 3709\u20133716. https:\/\/doi.org\/10.1002\/jmv.26202 (2020).","journal-title":"J. Med. Virol."},{"key":"54471_CR2","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3389\/fimmu.2019.02193","volume":"10","author":"HM Long","year":"2019","unstructured":"Long, H. M., Meckiff, B. J. & Taylor, G. S. The T-cell response to Epstein\u2013Barr virus\u2013new tricks from an old dog. Front. Immunol. 10, 2193. https:\/\/doi.org\/10.3389\/fimmu.2019.02193 (2019).","journal-title":"Front. Immunol."},{"key":"54471_CR3","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.4049\/jimmunol.1900377","volume":"203","author":"BJ Meckiff","year":"2019","unstructured":"Meckiff, B. J. et al. Primary EBV infection induces an acute wave of activated antigen-specific cytotoxic CD4\u2009+\u2009T cells. J. Immunol. 203, 1276\u20131287. https:\/\/doi.org\/10.4049\/jimmunol.1900377 (2019).","journal-title":"J. Immunol."},{"key":"54471_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.hbpd.2019.12.005","volume":"19","author":"T Qin","year":"2020","unstructured":"Qin, T. et al. Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation: A single-center experience. Hepatobiliary Pancreat. Dis. Int. 19, 3\u201311. https:\/\/doi.org\/10.1016\/j.hbpd.2019.12.005 (2020).","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"54471_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1365-2141.2005.05452.x","volume":"129","author":"H Williams","year":"2005","unstructured":"Williams, H. et al. The immune response to primary EBV infection: A role for natural killer cells. Br. J. Haematol. 129, 266\u2013274. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05452.x (2005).","journal-title":"Br. J. Haematol."},{"key":"54471_CR6","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1111\/tri.14107","volume":"34","author":"JY Liu","year":"2021","unstructured":"Liu, J. Y., Zhang, J. M., Zhan, H. S., Sun, L. Y. & Wei, L. EBV-specific cytotoxic T lymphocytes for refractory EBV-associated post-transplant lymphoproliferative disorder in solid organ transplant recipients: A systematic review. Transpl. Int. 34, 2483\u20132493. https:\/\/doi.org\/10.1111\/tri.14107 (2021).","journal-title":"Transpl. Int."},{"key":"54471_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fonc.2019.00127","volume":"9","author":"JP Dugan","year":"2019","unstructured":"Dugan, J. P., Coleman, C. B. & Haverkos, B. Opportunities to target the life cycle of Epstein\u2013Barr virus (EBV) in EBV-associated lymphoproliferative disorders. Front. Oncol. 9, 127. https:\/\/doi.org\/10.3389\/fonc.2019.00127 (2019).","journal-title":"Front. Oncol."},{"key":"54471_CR8","doi-asserted-by":"publisher","first-page":"e13652","DOI":"10.1111\/ctr.13652","volume":"33","author":"UD Allen","year":"2019","unstructured":"Allen, U. D. & Preiksaitis, J. K. Infectious Diseases Community of Practice, A. Post-transplant lymphoproliferative disorders, Epstein\u2013Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transpl. 33, e13652. https:\/\/doi.org\/10.1111\/ctr.13652 (2019).","journal-title":"Clin. Transpl."},{"key":"54471_CR9","doi-asserted-by":"publisher","first-page":"e14292","DOI":"10.1111\/petr.14292","volume":"26","author":"J Quintero Bernabeu","year":"2022","unstructured":"Quintero Bernabeu, J. et al. Epstein\u2013Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr. Transpl. 26, e14292. https:\/\/doi.org\/10.1111\/petr.14292 (2022).","journal-title":"Pediatr. Transpl."},{"key":"54471_CR10","unstructured":"Swerdlow, S., Webber, S. & Ferry, J. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, vol. 2 (eds Swerdlow, S. et al.) 453\u2013464 (AARC, 2008)."},{"key":"54471_CR11","doi-asserted-by":"publisher","first-page":"e70501","DOI":"10.1002\/jmv.70501","volume":"97","author":"L Lyu","year":"2025","unstructured":"Lyu, L., Li, Q. & Wang, C. EBV Latency Programs: Molecular and Epigenetic Regulation and Its Role in Disease Pathogenesis. J. Med. Virol. 97, e70501. https:\/\/doi.org\/10.1002\/jmv.70501 (2025).","journal-title":"J. Med. Virol."},{"key":"54471_CR12","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1073\/pnas.0813320106","volume":"106","author":"MH Fogg","year":"2009","unstructured":"Fogg, M. H., Wirth, L. J., Posner, M. & Wang, F. Decreased EBNA-1-specific CD8\u2009+\u2009T cells in patients with Epstein\u2013Barr virus-associated nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. U S A. 106, 3318\u20133323. https:\/\/doi.org\/10.1073\/pnas.0813320106 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"54471_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1172\/JCI10209","volume":"107","author":"K Bickham","year":"2001","unstructured":"Bickham, K. et al. EBNA1-specific CD4\u2009+\u2009T cells in healthy carriers of Epstein\u2013Barr virus are primarily Th1 in function. J. Clin. Investig. 107, 121\u2013130. https:\/\/doi.org\/10.1172\/JCI10209 (2001).","journal-title":"J. Clin. Investig"},{"key":"54471_CR14","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.4049\/jimmunol.180.3.1643","volume":"180","author":"TA Haigh","year":"2008","unstructured":"Haigh, T. A. et al. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMP-specific CD4\u2009+\u2009cytotoxic T cell recognition of ebv-transformed B cell lines1. J. Immunol. 180, 1643\u20131654. https:\/\/doi.org\/10.4049\/jimmunol.180.3.1643 (2008).","journal-title":"J. Immunol."},{"key":"54471_CR15","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3390\/v13122344","volume":"13","author":"T Murata","year":"2021","unstructured":"Murata, T. et al. Molecular basis of Epstein\u2013Barr virus latency establishment and lytic reactivation. Viruses 13, 2344. https:\/\/doi.org\/10.3390\/v13122344 (2021).","journal-title":"Viruses"},{"key":"54471_CR16","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/2326-6066.CIR-14-0242","volume":"3","author":"AS Hartlage","year":"2015","unstructured":"Hartlage, A. S. et al. The Epstein\u2013Barr virus lytic protein BZLF1 as a candidate target antigen for vaccine development. Cancer Immunol. Res. 3, 787\u2013794. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0242 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"54471_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5501\/wjv.v1.i1.31","volume":"1","author":"M De Paschale","year":"2012","unstructured":"De Paschale, M. & Clerici, P. Serological diagnosis of Epstein-Barr virus infection: Problems and solutions. World J. Virol. 1, 31\u201343. https:\/\/doi.org\/10.5501\/wjv.v1.i1.31 (2012).","journal-title":"World J. Virol."},{"key":"54471_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/cei.12337","volume":"177","author":"D C\u00e1rdenas Sierra","year":"2014","unstructured":"C\u00e1rdenas Sierra, D., V\u00e9lez Colmenares, G., Orfao de Matos, A., Fiorentino G\u00f3mez, S. & Quijano G\u00f3mez, S. M. Age-associated Epstein\u2013Barr virus-specific T cell responses in seropositive healthy adults. Clin. Exp. Immunol. 177, 320\u2013332. https:\/\/doi.org\/10.1111\/cei.12337 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"54471_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood-2007-07-101907","volume":"111","author":"S Bhaduri-McIntosh","year":"2008","unstructured":"Bhaduri-McIntosh, S., Rotenberg, M. J., Gardner, B., Robert, M. & Miller, G. Repertoire and frequency of immune cells reactive to Epstein\u2013Barr virus-derived autologous lymphoblastoid cell lines. Blood 111, 1334\u20131343. https:\/\/doi.org\/10.1182\/blood-2007-07-101907 (2008).","journal-title":"Blood"},{"key":"54471_CR20","doi-asserted-by":"publisher","first-page":"105443","DOI":"10.1016\/j.meegid.2023.105443","volume":"112","author":"M Liu","year":"2023","unstructured":"Liu, M., Wang, R. & Xie, Z. T cell-mediated immunity during Epstein\u2013Barr virus infections in children. Infect. Genet. Evol. 112, 105443. https:\/\/doi.org\/10.1016\/j.meegid.2023.105443 (2023).","journal-title":"Infect. Genet. Evol."},{"key":"54471_CR21","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.200940000","volume":"40","author":"M Guerreiro","year":"2010","unstructured":"Guerreiro, M. et al. Human peripheral blood and bone marrow Epstein\u2013Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets. Eur. J. Immunol. 40, 1566\u20131576. https:\/\/doi.org\/10.1002\/eji.200940000 (2010).","journal-title":"Eur. J. Immunol."},{"key":"54471_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/QCO.0000000000000787","volume":"34","author":"J Lindsay","year":"2021","unstructured":"Lindsay, J., Othman, J., Heldman, M. R. & Slavin, M. A. Epstein\u2013Barr virus posttransplant lymphoproliferative disorder: update on management and outcomes. Curr. Opin. Infect. Dis. 34, 635\u2013645 (2021).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"54471_CR23","doi-asserted-by":"publisher","first-page":"e13666","DOI":"10.1111\/petr.13666","volume":"24","author":"E Seo","year":"2020","unstructured":"Seo, E. et al. Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients. Pediatr. Transpl. 24, e13666. https:\/\/doi.org\/10.1111\/petr.13666 (2020).","journal-title":"Pediatr. Transpl."},{"key":"54471_CR24","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1097\/TP.0000000000004919","volume":"108","author":"PL Furlano","year":"2024","unstructured":"Furlano, P. L., B\u00f6hmig, G. A., Puchhammer-St\u00f6ckl, E. & Vietzen, H. Mechanistic understanding of EBV+lymphoproliferative disease development after transplantation. Transplantation 108, 1867\u20131881 (2024).","journal-title":"Transplantation"},{"key":"54471_CR25","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1182\/blood-2002-01-0210","volume":"100","author":"P Porcu","year":"2002","unstructured":"Porcu, P. et al. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8\u2009+\u2009T-cell restoration. Blood 100, 2341\u20132348. https:\/\/doi.org\/10.1182\/blood-2002-01-0210 (2002).","journal-title":"Blood"},{"key":"54471_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/vaccines9060555","volume":"9","author":"EH Ahmed","year":"2021","unstructured":"Ahmed, E. H. et al. Targeted delivery of BZLF1 to DEC205 drives EBV-protective immunity in a spontaneous model of EBV-driven lymphoproliferative disease. Vaccines 9, 555. https:\/\/doi.org\/10.3390\/vaccines9060555 (2021).","journal-title":"Vaccines"},{"key":"54471_CR27","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.jfma.2018.12.007","volume":"118","author":"HS Chen","year":"2019","unstructured":"Chen, H. S. et al. Roles of Epstein\u2013Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation. J. Formos. Med. Assoc. 118, 1362\u20131368. https:\/\/doi.org\/10.1016\/j.jfma.2018.12.007 (2019).","journal-title":"J. Formos. Med. Assoc."},{"key":"54471_CR28","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1182\/blood.2020005466","volume":"139","author":"K Toner","year":"2022","unstructured":"Toner, K. & Bollard, C. M. EBV+ lymphoproliferative diseases: Opportunities for leveraging EBV as a therapeutic target. Blood 139, 983\u2013994. https:\/\/doi.org\/10.1182\/blood.2020005466 (2022).","journal-title":"Blood"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54471-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54471-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54471-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:21:23Z","timestamp":1785885683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54471-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54471"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54471-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Human Research Ethics Committee, Faculty of Medicine Ramathibodi Hospital, Mahidol University, approved this study (reference number: MURA2018\/652). The liver transplantation service was performed under Thai organ donation law and regulation with consents from the donors and recipients or their legal guardians. No organs were transferred from the prisoners. The study has followed the Helsinki Declaration. This study did not involve any clinical trial, and therefore the clinical trial number was not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was completed by the patient\u2019s legal guardians, and an assent form was obtained from children aged\u2009\u2265\u20097 years.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24083"}}